New Melanoma Drug May Extend Survival

<p>MONDAY, Jun 25 (HealthDay News) — New investigate suggests that a
new drug does a improved pursuit of combating <span>advanced skin cancer</span> in <span>melanoma</span>
patients than chemotherapy.</p>
<p>However, patients typically still got worse after usually a few months on
the drug.</p>
<p>The drug, called <span>dabrafenib</span>, blocks a signaling protein and is used to
treat melanomas with a specific <span>genetic mutation</span>. About half of melanoma
patients have this mutation.</p>
<p>In a proviso 3 hearing saved by a drug’s maker, GlaxoSmithKline, an
international organisation of researchers led by <span>Dr. Axel Hauschild</span> of the
Schleswig-Holstein University Hospital in <span>Kiel, Germany</span>, gave dabrafenib
or a many common existent treatment, dacarbazine (DTIC-Dome), to 250
patients with swelling or inoperable melanoma. About half responded
...